Literature DB >> 15122709

The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.

Paola Cinque1, Manuela Nebuloni, Maria Lisa Santovito, Richard W Price, Magnus Gisslen, Lars Hagberg, Arabella Bestetti, Gianluca Vago, Adriano Lazzarin, Francesco Blasi, Nicolai Sidenius.   

Abstract

The urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in extracellular matrix degradation and cell migration in the central nervous system (CNS). To investigate the role of the uPA/uPAR system in the pathophysiology of acquired immunodeficiency syndrome dementia complex (ADC), we measured soluble uPAR (suPAR) levels in cerebrospinal fluid (CSF) and plasma from human immunodeficiency virus (HIV)-1-infected patients and controls. CSF suPAR levels were significantly higher in HIV-1-infected patients than in controls and in patients with ADC or opportunistic CNS infections (CNS-OIs) than in neurologically asymptomatic patients, irrespective of HIV-1 disease stage. The highest levels of suPAR were found in patients with ADC, and among those with CNS-OIs in patients with cytomegalovirus encephalitis or cryptococcosis. Plasma suPAR levels were higher in HIV-1-infected patients than in controls and increased with HIV-1 disease stage regardless of the presence of CNS disease. In patients with ADC or CNS-OIs, CSF suPAR levels correlated with CSF HIV-1 RNA, but not with plasma suPAR concentrations. Highly active antiretroviral therapy was associated with a significant and parallel decrease of both CSF suPAR and HIV-1 RNA. In brain tissue from patients with HIV-1 encephalitis, uPAR was highly expressed by microglial and multinucleated giant cells staining positively for HIV-1. The overexpression of uPAR in the CNS of patients with ADC suggests that the uPA/uPAR system may contribute to the tissue injury and neuronal damage in this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122709     DOI: 10.1002/ana.20076

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

1.  HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress.

Authors:  Jean-Pierre Louboutin; Lokesh Agrawal; Beverly A S Reyes; Elisabeth J Van Bockstaele; David S Strayer
Journal:  J Neuropathol Exp Neurol       Date:  2010-08       Impact factor: 3.685

2.  Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.

Authors:  Rick B Meeker; Winona Poulton; Silva Markovic-Plese; Colin Hall; Kevin Robertson
Journal:  J Neurovirol       Date:  2011-05-10       Impact factor: 2.643

3.  Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.

Authors:  G Tzanakaki; M Paparoupa; M Kyprianou; A Barbouni; J Eugen-Olsen; J Kourea-Kremastinou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-05       Impact factor: 3.267

4.  Beneficial Effects of Cannabis on Blood-Brain Barrier Function in Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Scott Peterson; Mariana Cherner; Erin Morgan; Rachel Schrier; Bin Tang; Martin Hoenigl; Scott Letendre; Jenny Iudicello
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

5.  Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients.

Authors:  Ase B Andersen; Ian Law; Karen S Krabbe; Helle Bruunsgaard; Sisse R Ostrowski; Henrik Ullum; Liselotte Højgaard; Annemette Lebech; Jan Gerstoft; Andreas Kjaer
Journal:  J Neuroinflammation       Date:  2010-02-14       Impact factor: 8.322

Review 6.  Host hindrance to HIV-1 replication in monocytes and macrophages.

Authors:  Anna Bergamaschi; Gianfranco Pancino
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

7.  Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Authors:  Massimo Alfano; Samanta A Mariani; Chiara Elia; Ruggero Pardi; Francesco Blasi; Guido Poli
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

8.  Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases.

Authors:  Manuela Nebuloni; Paola Cinque; Nicolai Sidenius; Angelita Ferri; Eleonora Lauri; Elisabetta Omodeo-Zorini; Pietro Zerbi; Luca Vago
Journal:  J Neurovirol       Date:  2008-12-24       Impact factor: 2.643

9.  Plasma (1 → 3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis.

Authors:  Sara Gianella; Scott L Letendre; Jennifer Iudicello; Donald Franklin; Thaidra Gaufin; Yonglong Zhang; Magali Porrachia; Milenka Vargas-Meneses; Ronald J Ellis; Malcolm Finkelman; Martin Hoenigl
Journal:  J Neurovirol       Date:  2019-07-11       Impact factor: 2.643

10.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.